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background
 
Untreated, one third of patients who undergo surgery will have postoperative nausea
and vomiting. Although many trials have been conducted, the relative benefits of pro-
phylactic antiemetic interventions given alone or in combination remain unknown.
 
methods
 
We enrolled 5199 patients at high risk for postoperative nausea and vomiting in a ran-
domized, controlled trial of factorial design that was powered to evaluate interactions
among as many as three antiemetic interventions. Of these patients, 4123 were ran-
domly assigned to 1 of 64 possible combinations of six prophylactic interventions:
4 mg of ondansetron or no ondansetron; 4 mg of dexamethasone or no dexamethasone;
1.25 mg of droperidol or no droperidol; propofol or a volatile anesthetic; nitrogen or
nitrous oxide; and remifentanil or fentanyl. The remaining patients were randomly as-
signed with respect to the first four interventions. The primary outcome was nausea
and vomiting within 24 hours after surgery, which was evaluated blindly.
 
results
 
Ondansetron, dexamethasone, and droperidol each reduced the risk of postoperative
nausea and vomiting by about 26 percent. Propofol reduced the risk by 19 percent, and
nitrogen by 12 percent; the risk reduction with both of these agents (i.e., total intrave-
nous anesthesia) was thus similar to that observed with each of the antiemetics. All the
interventions acted independently of one another and independently of the patients’
baseline risk. Consequently, the relative risks associated with the combined interventions
could be estimated by multiplying the relative risks associated with each intervention.
Absolute risk reduction, though, was a critical function of patients’ baseline risk.
 
conclusions
 
Because antiemetic interventions are similarly effective and act independently, the safest
or least expensive should be used first. Prophylaxis is rarely warranted in low-risk pa-
tients, moderate-risk patients may benefit from a single intervention, and multiple in-
terventions should be reserved for high-risk patients.
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nesthesia is given to more than
 
75 million surgical patients annually,
worldwide. Untreated, one third will have
postoperative nausea, vomiting, or both.
 
1-3
 
 Patients
often rate postoperative nausea and vomiting as
worse than postoperative pain.
 
4,5
 
 It is not surpris-
ing, therefore, that prevention of postoperative nau-
sea and vomiting improves satisfaction among pa-
tients who are likely to experience them.
 
6
 
 Vomiting
increases the risk of aspiration and has been asso-
ciated with suture dehiscence, esophageal rupture,
subcutaneous emphysema, and bilateral pneumo-
thoraxes.
 
7,8
 
 Postoperative nausea and vomiting fre-
quently delay discharge from postanesthesia care
units, and they are the leading cause of unexpected
hospital admission after planned ambulatory sur-
gery.
 
9
 
 The annual cost of postoperative nausea and
vomiting in the United States is thought to be sev-
eral hundred million dollars.
 
10,11
 
More than 1000 randomized, controlled trials
have evaluated pharmacologic methods of prevent-
ing and treating postoperative nausea and vomit-
ing. Most have compared a single intervention with
placebo. Serotonin (5-hydroxytryptamine type 3)
antagonists (e.g., ondansetron), dexamethasone
(a corticosteroid), and droperidol (a neuroleptic
drug) are among the best-studied antiemetic agents.
Alternatively, the avoidance of emetogenic factors
during anesthesia can reduce the baseline risk of
postoperative nausea and vomiting. This strategy
includes the use of propofol instead of volatile an-
esthetics, the substitution of nitrogen for nitrous
oxide, and the use of remifentanil, an ultra–short-
acting opioid, instead of fentanyl.
 
12,13
 
The limited efficacy of treatment with single
antiemetics
 
14
 
 has prompted evaluations of several
antiemetic strategies used in combination.
 
15
 
 How-
ever, no previous study of postoperative nausea and
vomiting has had an appropriate design or suffi-
cient power to evaluate all the major pharmacolog-
ic interventions simultaneously or to determine the
extent to which combining multiple interventions
improves outcome. A recent consensus conference
was thus unable to support a definitive statement on
the benefits of combining antiemetic strategies.
 
16
 
We therefore conducted a large clinical trial of fac-
torial design with sufficient power to compare the
efficacy of six well-established antiemetic strategies
and to determine the extent to which efficacy could
be improved by combining two or three interven-
tions.
The design of the study, the recruitment of patients
at each center, the acquisition and management of
data, the statistical analyses, the interpretation of
the data, and the writing and editing of the manu-
script were performed independently of the spon-
sors. The contributions of the individual authors
are listed in the Appendix.
After obtaining approval from the institutional
review boards of the 28 participating centers, we en-
rolled 5199 adults who were scheduled to undergo
elective surgery during general anesthesia that was
expected to last at least one hour. All the patients had
a risk of postoperative nausea and vomiting that ex-
ceeded 40 percent, according to a simplified risk
score,
 
17 
 
based on the presence of at least two of the
following risk factors: female sex, nonsmoker sta-
tus, previous history of postoperative nausea and
vomiting or motion sickness, and anticipated use
of postoperative opioids.
 
18,19
 
 We excluded patients
in whom any of the study drugs were contraindicat-
ed, those who had taken emetogenic or antiemetic
drugs within the 24 hours before surgery, those who
were expected to require postoperative mechanical
ventilation, and those who were pregnant or lactat-
ing. All the patients provided their written informed
consent.
 
protocol
 
The antiemetic efficacy of six individual treatments
and combinations of them was simultaneously
evaluated according to a 2
 
6
 
 factorial design.
 
20
 
 Three
of the prophylactic interventions involved the use of
an antiemetic drug: ondansetron, dexamethasone,
or droperidol. The other three interventions con-
sisted of the use of propofol instead of a volatile an-
esthetic, the omission of nitrous oxide, and the
substitution of remifentanil for fentanyl. Thus, ac-
cording to the study design, each patient was to be
randomly assigned to one of each of the following
six interventions: ondansetron (4 mg intravenously)
or no ondansetron; dexamethasone (4 mg intrave-
nously) or no dexamethasone; droperidol (1.25 mg
intravenously) or no droperidol; propofol or a vola-
tile anesthetic (i.e., isoflurane, desflurane, or sevo-
flurane) in a 2:1 ratio; nitrogen or nitrous oxide;
and remifentanil or fentanyl.
These 6 treatments lead to a possible 64 (i.e., 2
 
6
 
)
different treatment combinations. However, propo-
fol is associated with a reduced risk of postopera-
a methods
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tive nausea and vomiting,
 
21
 
 so to ensure sufficient
power to quantify the effect of antiemetics in the
propofol subgroup, we assigned twice as many pa-
tients to propofol as to volatile anesthetics (for a 2:1
randomization ratio). Therefore, permuted blocks
of 96 (2
 
3
 
¬3¬2
 
2
 
) patients were generated. Each cen-
ter received four blocks with a unique computerized
randomization, stored in sequentially numbered,
sealed, opaque envelopes. 
The envelopes were opened after consent was
obtained, just before the induction of general anes-
thesia. The anesthesiologists responsible for intra-
operative management were not blinded to the treat-
ment, but they were not involved in the postoperative
assessment. Supplemental oxygen may
 
22,23
 
 or may
not
 
24,25
 
 have an antiemetic effect. Consequently, at
three centers patients were randomly assigned to
30 percent oxygen in nitrous oxide, 30 percent oxy-
gen in nitrogen, or 80 percent oxygen in nitrogen,
in a randomization ratio of 1:1:1. As a result, a min-
imum of 144 (3¬48) patients were required per
block. To provide sufficient power, each center
agreed to study 288 patients, twice as many as the
minimum.
The patients were given premedication with a
benzodiazepine. Three minutes before the induc-
tion of anesthesia, they received either a bolus of
fentanyl (100 to 200 µg) or an infusion of remifen-
tanil (0.25 µg per kilogram of body weight per min-
ute), according to the treatment to which they had
been assigned. Anesthesia was induced with intra-
venous propofol (Disoprivan or Diprivan, Astra-
Zeneca) at a dose of 2 to 3 mg per kilogram, and tra-
cheal intubation was facilitated with rocuronium.
Normocapnic mechanical ventilation was insti-
tuted with the assigned gas combination. Anesthe-
sia was maintained with either propofol (starting at
about 80 µg per kilogram per hour) or a standard-
ized concentration of a volatile anesthetic. If the
heart rate or blood pressure deviated by more than
20 percent from the preoperative value, an intrave-
nous bolus of fentanyl (50 to100 µg) was given or the
rate of remifentanil infusion was increased slightly.
In addition, the concentration of volatile anesthetics
or the propofol infusion rate could be adjusted as
clinically appropriate. In the designated patients,
4 mg of dexamethasone (if assigned) and 1.25 mg
of droperidol (if assigned) were given intravenously
within 20 minutes after the start of anesthesia,
 
10,26
 
and 4 mg of ondansetron (if assigned) was given in-
travenously during the last 20 minutes of surgery.
 
27
 
Postoperatively, the patients received supple-
mental oxygen, and pain was ameliorated with the
use of nonsteroidal antiinflammatory medications
administered intraoperatively. The patients who had
been assigned to receive intraoperative remifentanil
were given 50 µg of morphine per kilogram or an
equivalent opioid at the end of surgery. The need
for a postoperative opioid was left to the discretion
of the anesthesiologist, and the dose was adjusted
according to clinical needs. Patients who requested
antiemetic therapy or who had an emetic episode
were given 4 mg of ondansetron; if symptoms per-
sisted, 4 mg of dexamethasone and 1.25 mg of dro-
peridol were added.
 
measurements
 
Our primary outcome measure was the incidence of
any nausea, emetic episodes (retching or vomiting),
or both (i.e., postoperative nausea and vomiting)
during the first 24 postoperative hours. After the
2nd and 24th postoperative hours, trained investi-
gators who were fully blinded to the intraoperative
management and random treatment assignments
recorded the number of emetic episodes and the
time each one occurred. At both these time points,
patients orally rated their worst nausea episode dur-
ing the preceding interval on an 11-point scale,
where 0 represented no nausea and 10 the most
severe nausea possible.
 
statistical analysis
 
Different sample-size estimations were performed
and indicated that about 5000 patients would be
needed for the analysis of interactions involving as
many as three factors, whereas the number of pa-
tients required for the analysis of two-factor inter-
actions or of single factors was considerably small-
er.
 
20
 
 An interaction was defined as present if the
effect of two factors in combination was signifi-
cantly different from the separate effects of each
factor multiplied together on an odds-ratio scale.
For each of the six randomized treatments, the
numbers of patients who had postoperative nausea
and vomiting were compared with the use of chi-
square tests for each main effect, and reductions
in the relative risk of nausea and vomiting were
estimated. Logistic-regression analyses were used
to quantify the relative effects of the six interven-
tions as odds ratios and to identify potential two-
or three-factor interactions by a stepwise forward-
inclusion algorithm. This analysis was repeated
to compensate for the specified covariates (female
sex, nonsmoking status, age, a history of postoper-
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ative nausea and vomiting or motion sickness, use
of postoperative opioids, type of surgery, and study
center). A two-sided P value of less than 0.05 was
considered to indicate statistical significance.
Patients were recruited from February 2, 2000, un-
til July 30, 2002, at 28 centers; 5199 patients under-
went factorial randomization to ondansetron or
no ondansetron, dexamethasone or no dexameth-
asone, droperidol or no droperidol, and propofol or
a volatile anesthetic. Outcome data were incomplete
for 38 patients, leaving 5161 patients (99 percent)
for whom complete outcome data were available.
One center each did not randomize with respect to
carrier gas (424 patients), use of remifentanil or fen-
tanyl (191 patients), or both of these factors (181
patients). Three centers randomly assigned a total
of 280 patients to 80 percent oxygen in nitrogen (as
a third alternative to 30 percent oxygen in nitrogen
or in nitrous oxide). A total of 4123 patients were
thus randomly assigned with respect to all six pri-
mary factors, and outcome data were incomplete
in 37 of them (1 patient with incomplete data was
among those not randomly assigned with respect
to carrier gas), leaving 4086 patients (99 percent) for
whom complete outcome data could be analyzed
(Fig. 1).
Of the 5161 patients, 81.5 percent were women,
81.2 percent were nonsmokers, 54.5 percent had a
history of postoperative nausea and vomiting or mo-
tion sickness, and 78.1 percent received postopera-
tive opioids. Hernia repair was performed in 2.8 per-
cent of the patients, cholecystectomy in 7.7 percent,
hysterectomy in 16.9 percent, thyroid surgery in 5.9
percent, breast surgery in 2.8 percent, hip replace-
ment in 3.5 percent, knee arthroscopy in 2.2 per-
cent, arm or hand surgery in 2.5 percent, head and
neck surgery (including ophthalmic surgery) in 9.0
percent, gynecologic surgery other than hysterecto-
my in 28.2 percent, other bone surgery in 6.6 per-
cent, and other types of general surgery in 11.7 per-
cent. The baseline characteristics were similar
among the patients randomly assigned to each
intervention; more detailed information can be
found in Table S1 of the Supplementary Appendix
(available with the full text of this article at www.
nejm.org).
Overall, 1731 of 5161 patients (34 percent) had
postoperative nausea and vomiting. This reflects the
average incidence among all 64 possible combina-
tions of interventions, which ranged from 59 per-
cent among patients who were given volatile anes-
thesia, nitrous oxide, fentanyl, and no antiemetics
(26 of 44 of these patients had nausea and vomit-
ing) to 17 percent among patients who received pro-
pofol, nitrogen, remifentanil, ondansetron, dexa-
methasone, and droperidol (17 of 102 of these
patients had nausea and vomiting). Nausea occurred
in 1617 patients (31 percent) and vomiting in 734
(14 percent). Among the patients who had symp-
toms, the median and mean ratings for the maximal
nausea level were 5 and 5.7, respectively, and the
median and mean numbers of emetic episodes were
1 and 1.5, respectively. According to bivariate analy-
ses, each antiemetic reduced the incidence of post-
operative nausea and vomiting by about 26 percent,
propofol reduced it by about 19 percent, and nitro-
gen reduced it by about 12 percent (Table 1). The
rates of hypotension, use of intraoperative vasocon-
strictors, and shivering were similar with each anti-
emetic. Propofol was associated with less frequent
use of intraoperative vasoconstrictors (15 percent)
than were volatile anesthetics (20 percent, P=0.001).
The use of remifentanil rather than fentanyl did not
significantly reduce the incidence of postoperative
nausea and vomiting, but it was associated with in-
creased use of intraoperative vasoconstrictors (21
percent, vs. 13 percent with fentanyl; P<0.001) and
an increased incidence of shivering (6.7 percent,
vs. 3.3 percent with fentanyl; P<0.001).
Increasing the number of antiemetics adminis-
tered reduced the incidence of postoperative nausea
and vomiting from 52 percent when no antiemetics
were used to 37 percent, 28 percent, and 22 percent
when one, two, and three antiemetics, respectively,
were administered (Fig. 2). This corresponds to a
26 percent reduction in the relative risk of nausea
and vomiting for each additional antiemetic used
(95 percent confidence interval, 23 percent to 30
percent). Furthermore, there were no significant
differences among the antiemetics (chi-square=
0.01, 2 df; P=1.00) or among any pair of antiemet-
ics (chi-square=0.42, 2 df; P=0.81).
The effects of the anesthetic interventions and
their combinations were explored in the 4086 pa-
tients who were randomly assigned with respect to
all six interventions. The average incidence of post-
operative nausea and vomiting was 41 percent
among those given a volatile anesthetic and nitrous
oxide, 34 percent among those given a volatile an-
esthetic and nitrogen, 32 percent among those given
propofol and nitrous oxide, and 29 percent among
results
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those given propofol and nitrogen. Figure 3 shows
these incidences broken down according to the
number of antiemetics. There was no significant
interaction between propofol and nitrogen (chi-
square=0.94, 2 df, by the likelihood ratio test;
P=0.33). Although the type of volatile anesthetic
(isoflurane, sevoflurane, or desflurane) was not a
randomized factor, it had no significant effect on
the incidence of postoperative nausea and vomiting
in a multivariate model (P=0.30). The incidence of
postoperative nausea and vomiting was 31 percent
among the patients who received 80 percent oxygen
in nitrogen and 24 percent among those who re-
ceived 30 percent oxygen in nitrogen (P=0.07).
Multivariate logistic analyses of data from all
5161 patients and of data from the 4086 patients
assigned with respect to all six treatments are shown
in Table 2. This analysis found no significant inter-
actions among the treatments. When the interac-
tions between treatments and potentially confound-
ing factors (e.g., the type of surgery) were analyzed,
only one significant interaction was detected: an in-
teraction between droperidol and sex (P=0.003).
Droperidol significantly reduced the risk of post-
operative nausea and vomiting among women, but
not among men: 910 of the 2106 women who did
not receive droperidol had nausea or vomiting (43
percent), as compared with 662 of the 2101 women
who did receive this agent (32 percent) (odds ratio,
0.61; 95 percent confidence interval, 0.53 to 0.69;
P<0.001), and the effect was independent of men-
strual-cycle phase or whether menopause had oc-
curred; in contrast, 79 of the 482 men who did not
receive droperidol had nausea or vomiting (16 per-
cent), as compared with 80 of the 472 men who did
receive this agent (17 percent) (odds ratio, 1.04; 95
percent confidence interval, 0.74 to 1.46; P=0.82).
The results based on analyses of data from 4086
patients remained essentially unchanged when data
from all 5161 patients were considered or when po-
tential confounders were included in the statistical
models (Table 2). Detailed results for the 4086 pa-
tients in the 64 groups are given in Table S2 of the
Supplementary Appendix. Given the finding that to-
tal intravenous anesthesia or the use of any anti-
emetic independently reduced the risk of postoper-
ative nausea and vomiting by about 26 percent, the
incidence of postoperative nausea and vomiting for
five different initial risks was calculated for as many
as four interventions (Table 3).
The large enrollment and the factorial design of our
trial allowed simultaneous evaluation of the anti-
emetic efficacy of three antiemetic interventions and
three anesthetic interventions and of all possible
combinations of two or three interventions. All the
tested antiemetics appeared to be similarly effective.
Ondansetron and other 5-hydroxytryptamine type 3
antagonists are considered relatively safe, but they
are more expensive than droperidol and dexameth-
asone. However, low-dose droperidol can cause dys-
phoria,
 
28,29
 
 and the Food and Drug Administration
discussion
 
* CI denotes confidence interval.
† P values were calculated by the chi-square test.
‡ The numbers shown are the numbers of patients who had postoperative nausea, vomiting, or both (PONV) divided by 
the total numbers of patients randomly assigned to the specified intervention for whom complete outcome data could 
be analyzed. The data are based on all 5161 randomly assigned patients who completed the study, with the exceptions of 
 
the data for carrier gas (4277 patients) and for remifentanil versus fentanyl (4789 patients).
 
Table 1. Risk of Postoperative Nausea and Vomiting According to Patients’ Randomly Assigned Interventions.
Intervention Received Intervention
Percent Relative
Risk (95% CI)*
P
Value†
 
Yes No
 
no. with PONV/total no. (%)
 
‡
Ondansetron (vs. no ondansetron) 735/2576 (28.5) 996/2585 (38.5) ¡26.0 (¡31.5 to ¡19.9) <0.001
Dexamethasone (vs. no dexamethasone) 739/2596 (28.5) 992/2565 (38.7) ¡26.4 (¡31.9 to ¡20.4) <0.001
Droperidol (vs. no droperidol) 742/2573 (28.8) 989/2588 (38.2) ¡24.5 (¡30.2 to ¡18.4) <0.001
Propofol (vs. inhalational anesthetic) 1066/3427 (31.1) 665/1734 (38.4) ¡18.9 (¡25.0 to ¡12.3) <0.001
Nitrogen as carrier gas (vs. nitrous oxide) 668/2146 (31.1) 755/2131 (35.4) ¡12.1 (¡19.3 to ¡4.3) 0.003
Remifentanil (vs. fentanyl) 827/2386 (34.7) 792/2403 (33.0) 5.2 (¡2.9 to 13.8) 0.21
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recently added a “black box” warning to the drug’s
labeling to indicate that it may be associated with
torsade de pointes; however, there is little evidence
that antiemetic doses trigger this condition.
 
30
 
 No
studies have identified complications associated
with the antiemetic dose of dexamethasone, al-
though even meta-analyses may have insufficient
power to detect rare complications.
 
31
 
 The combi-
nation of low cost and apparent safety makes dexa-
methasone at a dose of 4 mg an attractive first-line
agent for prophylaxis against postoperative nausea
and vomiting.
Bivariate analysis indicated that substituting
propofol for a volatile anesthetic reduced the risk
of postoperative nausea and vomiting by about 19
percent, whereas substituting nitrogen for nitrous
oxide reduced the risk by about 12 percent. Com-
bining these two anesthetic management strategies
(i.e., total intravenous anesthesia) thus reduced the
risk by about as much as any single antiemetic. In
contrast, the use of remifentanil instead of fentanyl
did not significantly reduce the risk of nausea and
vomiting.
The relative risk reduction associated with each
intervention was apparently independent for a wide
range of absolute risks. Thus, interventions that re-
duce the relative risk to a similar extent will provide
the greatest absolute risk reduction in patients most
likely to have postoperative nausea and vomiting.
For example, a single intervention in a patient with
an 80 percent risk of postoperative nausea and
vomiting will reduce the risk to 59 percent; the abso-
lute risk reduction is 21 percent, which translates
into a number needed to treat of about five to pre-
vent nausea and vomiting in one patient. Conversely,
the absolute risk reduction in a patient with a base-
line risk of 10 percent is only about 3 percent; this
corresponds to a number needed to treat of about
40, which would probably not justify the expense
and risk of prophylactic treatment. The efficacy of
an intervention thus depends critically on patients’
baseline risk.
Interestingly, there were no significant interac-
tions among the antiemetic interventions, among
the anesthetic interventions, or among the anti-
emetics and the anesthetics. The resulting relative
risk of nausea and vomiting associated with a com-
bination of interventions can thus be directly calcu-
lated as the product of the individual relative risks.
As a consequence, the absolute risk reduction pro-
vided by a second or third intervention is less than
that provided by the initial intervention (irrespective
 
Figure 2. Incidence of Postoperative Nausea and Vomiting Associated 
with the Various Combinations of Antiemetic Drugs.
 
The data shown represent outcomes in 5161 patients. Solid circles represent 
the average value for each number of prophylactic antiemetics, and open 
symbols the incidence for each antiemetic or combination of antiemetics. 
Ond denotes ondansetron, Dex dexamethasone, and Dro droperidol. 
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 bars 
represent 95 percent confidence intervals.
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Figure 3. Incidence of Postoperative Nausea and Vomiting According to
the Combinations of Anesthetic Strategies and the Number of Antiemetic 
Treatments Given. 
 
The data shown represent outcomes in 4086 patients. Because assignment to 
remifentanil did not contribute significantly to the risk of postoperative nau-
sea and vomiting, data pertaining to remifentanil are not shown. Although the 
graph suggests that there is an interaction between nitrogen (air) and propo-
fol in patients who received no antiemetic agents, statistical analyses did not 
confirm this impression. 
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 bars represent 95 percent confidence intervals.
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of which combination is chosen). A 70 percent re-
duction in the relative risk of postoperative nausea
and vomiting is thus the best that can be expected,
even when total intravenous anesthesia is used in
combination with three antiemetics.
Because each tested antiemetic agent and the
use of total intravenous anesthesia reduced the rel-
ative risk of nausea and vomiting to a similar extent,
the logical sequence is to use the least expensive or
safest intervention first. Additional interventions
that cost more or that are associated with a greater
chance of adverse effects will further reduce the ab-
solute risk, but to a lesser extent than will the initial
intervention. Combining prophylactic interventions
therefore markedly increases costs and the likeli-
hood of adverse effects while providing progressive-
ly less additional absolute benefit. Multiple interven-
tions should thus generally be reserved for patients
at high risk for postoperative nausea and vomiting
or those in whom nausea and vomiting would be es-
pecially dangerous.
In analyses based on the entire study population,
droperidol decreased the risk of postoperative nau-
sea and vomiting as much as did the other anti-
 
* The data are presented as odds ratios, which describe the effects of the interventions or covariates as compared with the 
effects when the intervention or covariate is absent. CI denotes confidence interval.
 
† Analyses were adjusted for the study center as a potentially confounding factor. 
 
Table 2. Results of Multiple Logistic-Regression Analysis and Odds Ratios for Postoperative Nausea and Vomiting.*
Variable
Patients Assigned with Respect
to Four Interventions
(N=5161)†
Patients Assigned with Respect
to Six Interventions
(N=4086)†
 
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Intervention
Ondansetron 0.56 (0.50–0.64) <0.001 0.56 (0.48–0.65) <0.001
Dexamethasone 0.57 (0.50–0.65) <0.001 0.57 (0.49–0.66) <0.001
Droperidol 0.58 (0.51–0.67) <0.001 0.56 (0.48–0.66) <0.001
Propofol 0.69 (0.60–0.79) <0.001 0.71 (0.61–0.83) <0.001
Carrier gas
Nitrogen (30% oxygen) 0.81 (0.70–0.93) 0.003 0.83 (0.72–0.97) 0.02
Nitrogen (80% oxygen) 0.99 (0.70–1.40) 0.96
Remifentanil 0.96 (0.84–1.10) 0.56 0.94 (0.81–1.09) 0.39
Covariate
Female sex 3.13 (2.33–4.20) <0.001 2.87 (2.08–3.95) <0.001
Interaction of droperidol and male sex 1.85 (1.26–2.72) 0.002 1.97 (1.29–3.00) 0.002
Nonsmoking 1.57 (1.32–1.87) <0.001 1.57 (1.29–1.91) <0.001
History of postoperative nausea and 
vomiting or motion sickness
1.70 (1.49–1.95) <0.001 1.80 (1.54–2.09) <0.001
Operation
Hernia repair 1.04 (0.65–1.67) 0.87 1.08 (0.66–1.78) 0.75
Cholecystectomy 1.49 (1.08–2.06) 0.015 1.44 (1.01–2.05) 0.04
Hysterectomy 1.78 (1.35–2.35) <0.001 1.94 (1.43–2.63) <0.001
Thyroid surgery 1.22 (0.86–1.72) 0.27 1.23 (0.85–1.78) 0.27
Breast surgery 0.74 (0.48–1.17) 0.20 0.76 (0.46–1.24) 0.27
Orthopedic surgery 0.91 (0.67–1.24) 0.55 0.91 (0.65–1.29) 0.60
Head and neck surgery 1.08 (0.71–1.65) 0.72 0.88 (0.55–1.42) 0.61
Other gynecologic surgery 0.91 (0.69–1.19) 0.48 0.98 (0.73–1.32) 0.91
Duration of anesthesia (per hr) 1.20 (1.12–1.28) <0.001 1.15 (1.06–1.24) 0.001
Use of postoperative opioids 2.14 (1.75–2.61) <0.001 2.01 (1.59–2.53) <0.001
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emetics, but when sex was considered, no signifi-
cant benefit was found in men. Such a finding has
not been described in previous studies, presumably
because many studies have been restricted to wom-
en and because studies that included both sexes
were too small to detect the interaction. Estrogen
or other hormonal factors seem unlikely to be the
cause, since the effectiveness of droperidol was in-
dependent from menstrual-cycle phase and meno-
pause (data not shown). It is possible that dopamine
is a more important trigger in women than in men.
It is also possible that the lack of efficacy of droperi-
dol in men is simply a spurious finding resulting
from multiple testing.
It is well known that the incidence of postoper-
ative nausea and vomiting varies considerably ac-
cording to the type of surgery conducted. However,
with the exception of hysterectomy and possibly
cholecystectomy, the relative risk was similar for all
types of surgery when corrected for major risk fac-
tors including sex, nonsmoking status, a history of
postoperative nausea and vomiting, and the use of
postoperative opioids. As a consequence, risk mod-
els that include the type of surgery
 
1,32
 
 do not pro-
vide greater predictive power than a simplified mod-
el.
 
18
 
,
 
19
 
 Since no interactions were detected between
the interventions and the type of surgery, it is not
necessary to repeat studies of postoperative nausea
and vomiting for various types of surgery.
 
14,33
 
Management techniques such as total intrave-
nous anesthesia cannot be used once postoperative
nausea and vomiting have begun. Dexamethasone,
similarly, prevents postoperative nausea and vomit-
ing only when given near the beginning of surgery,
probably by reducing surgery-induced inflamma-
tion.
 
34
 
 Moreover, “rescue” treatments are ineffec-
tive when the same drug has already been used pro-
phylactically.
 
35
 
 Postoperative treatment options are
thus limited when compared with the broader range
of prophylactic options, suggesting that prophylax-
is may be preferable to the treatment of established
postoperative nausea and vomiting. A reasonable
treatment strategy would be to use dexamethasone
and total intravenous anesthesia as first-line and
second-line methods of prophylaxis against post-
operative nausea and vomiting and to reserve sero-
tonin antagonists as a rescue treatment.
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* The baseline risk levels of 10 percent, 20 percent, 40 percent, 60 percent, and 
80 percent reflect the presence of 0, 1, 2, 3, and 4 risk factors, respectively, ac-
 
cording to a simplified risk score.
 
17
 
Table 3. Estimated Incidence of Postoperative Nausea and Vomiting 
as a Function of Baseline Risk, on the Basis of the Assumption That Each 
Intervention Reduces the Relative Risk by 26 Percent.
Baseline Risk
(No Intervention)* Estimated Incidence of Postoperative Nausea and Vomiting
 
One 
Intervention
Two 
Interventions
Three 
Interventions
Four 
Interventions
 
percent
 
10% 7 5 4 3
20% 15 11 8 6
40% 29 22 16 12
60% 44 33 24 18
80% 59 44 32 24
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